Correlation Between Acrivon Therapeutics, and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acrivon Therapeutics, Common and Molecular Partners AG, you can compare the effects of market volatilities on Acrivon Therapeutics, and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Molecular Partners.
Diversification Opportunities for Acrivon Therapeutics, and Molecular Partners
0.61 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Acrivon and Molecular is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Molecular Partners go up and down completely randomly.
Pair Corralation between Acrivon Therapeutics, and Molecular Partners
Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Acrivon Therapeutics, Common is 1.31 times less risky than Molecular Partners. The stock trades about -0.11 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about -0.08 of returns per unit of risk over similar time horizon. If you would invest 646.00 in Molecular Partners AG on August 28, 2024 and sell it today you would lose (84.00) from holding Molecular Partners AG or give up 13.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Acrivon Therapeutics, Common vs. Molecular Partners AG
Performance |
| Timeline |
| Acrivon Therapeutics, |
| Molecular Partners |
Acrivon Therapeutics, and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Acrivon Therapeutics, and Molecular Partners
The main advantage of trading using opposite Acrivon Therapeutics, and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| Acrivon Therapeutics, vs. Eliem Therapeutics | Acrivon Therapeutics, vs. HCW Biologics | Acrivon Therapeutics, vs. Scpharmaceuticals | Acrivon Therapeutics, vs. Milestone Pharmaceuticals |
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Complementary Tools
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |